Deutsche Bank Starts ARIAD Pharmaceuticals (ARIA) at Hold

November 3, 2016 6:50 AM EDT
Get Alerts ARIA Hot Sheet
Price: $23.74 +0.13%

Rating Summary:
    11 Buy, 13 Hold, 3 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 18 | Down: 19 | New: 11
Trade ARIA Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Deutsche Bank initiated coverage on ARIAD Pharmaceuticals (NASDAQ: ARIA) with a Hold rating and a price target of $9.50.

Analyst Andrew Peters said, "The pricing controversy in biopharma has recently hit Ariad, and hence we believe headline risk could overshadow any positive pipeline newsflow until the issue is resolved. Further, while we view ARIA as one of the most fundamentally solid companies in biotech with two commercial (or soon to be commercial) oncology assets, we expect shares to be range-bound in the nearterm as headline risk is weighed against the lack of clear value drivers over the next 12months. That said, we are positive on the company's longer-term fundamentals and its prospects for upside catalysts beyond that timeframe."

For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals click here. For more ratings news on ARIAD Pharmaceuticals click here.

Shares of ARIAD Pharmaceuticals closed at $9.01 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

Deutsche Bank

Add Your Comment